Clinical trials: Acute Optic Neuritis
Optic Neuritis
Adjunctive Gypenosides for Acute Optic Neuritis
This pilot randomized, double-blind, placebo-controlled trial evaluated whether short-course adjunctive gypenosides, added to standard corticosteroid treatment, may preserve retinal structural outcomes in adults with acute optic…
- Trial name
- NCT02976766
- Testing
- Gypenosides
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Multiple Sclerosis, NMO Spectrum Disorder
Tongji NADs Cohort
Neurological Autoimmune Diseases (NADs) are disorders caused by abnormal immune system attacks on neural tissues, affecting multiple systems including the central nervous system, peripheral nervous system, and neuromuscular…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
- Trial name
- NCT07333196
- Testing
- No active interventions
- Where
- China
- Volunteers
- 1,550 people
- Sponsor
- Tongji Hospital
Optic Neuritis, Multiple Sclerosis
Visual Reconstitution Therapy After Optic Neuritis
Incomplete remission after an optic neuritis attack is not uncommon. Visual reconstitution therapy is a software-based approach that has been shown to substantially improve residual visual field deficits in patients with pre- and…
- Trial name
- VISION (NCT01274702)
- Testing
- Visual Reconstitutions Therapy, Saccadic Eye Movement Training
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Friedemann Paul
Neuromyelitis Optica Spectrum Disorder
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
Neuromyelitis optica spectrum disorder (NMOSD) is one common demyelinating disease of the central nervous system in young adults, with high rate of disability and recurrence, and poor natural course, which can cause a serious…
- Trial name
- CAMPUS (NCT04064944)
- Testing
- blood purification equipment
- Volunteers
- 144 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Ublituximab (also known as LFB-R603) is a monoclonal antibody that specifically binds to the trans-membrane antigen CD20. The binding induces immune response that causes lysis of B cells.
- Trial name
- NCT02276963
- Testing
- Ublituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Demyelinating Disorders, Multiple Sclerosis
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
The participant will receive weekly intramuscular treatment with AVONEX® (interferon beta 1-a) and a one-time high dose intravenous methotrexate with Leucovorin rescue, along with the standard solumedrol treatment before…
- Conditions
- Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis
- Trial name
- NCT00037115
- Testing
- interferon beta 1a, methotrexate, methylprednisolone
- Where
- United States
- Sponsor
- MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Optic Neuritis, Multiple Sclerosis
Simvastatin Treatment of Patients With Acute Optic Neuritis
The purpose of this study is to investigate if the simvastatin treatment improve the visual function after 3 months of the inclusion to this project and if the simvastatin influences the results on cerebral MRI after 3 and 6…
- Trial name
- NCT00261326
- Testing
- simvastatin
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Acute Optic Neuritis
BIIB033 In Acute Optic Neuritis (AON)
The primary objective of the study is to evaluate the efficacy of BIIB033 in subjects with their first episode of unilateral acute optic neuritis (AON).
- Trial name
- NCT01721161
- Testing
- BIIB033 (anti-LINGO-1 mAb)
- Where
- 32 sites in Australia, Belgium and 9 more
- Volunteers
- 82 people
- Sponsor
- Biogen
Neurological Autoimmune Diseases
IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases
In this prospective controlled monocentric observational study, we assessed safety and efficacy of therapy with IA or PE in patients with neurological autoimmune diseases.
- Trial name
- NCT04687332
- Testing
- Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- University Medical Center Mainz
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
Multiple Sclerosis, Acute Optic Neuritis
Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB033-B and to compare the PK profile with that of BIIB033-A in healthy volunteers.
- Trial name
- NCT02833142
- Testing
- BIIB033 (opicinumab)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Biogen
Neuromyelitis Optica, Efgartigimod
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
This study aims to retrospective investigate the safety and effectiveness of Efgartigimod in the acute phase of neuromyelitis optica spectrum disorders (NMOSD) patients.
- Trial name
- NCT06118398
- Testing
- Intravenous methylprednisolone (IVMP) and Efgartigimod, IVMP
- Volunteers
- 24 people
- Sponsor
- Feng Jinzhou
Optic Neuritis
Lipoic Acid as a Treatment for Acute Optic Neuritis
The purpose of this study is to determine if oral lipoic acid can safely help relieve permanent optic nerve injury in patients diagnosed with acute optic neuritis.
- Trial name
- NCT01294176
- Testing
- Lipoic Acid
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Oregon Health and Science University
Optic Neuritis, Optic; Neuritis, With Demyelination
BN201 SAD MAD Study in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of BN201 in healthy subjects.
- Trial name
- NCT03630497
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Accure Therapeutics
Multiple Sclerosis
A Trial of Neuroprotection With ACTH in Acute Optic Neuritis
We hypothesize that the novel melanocortin-mediated anti-inflammatory effects of ACTH will reduce axonal loss following ON by limiting inflammatory optic nerve injury.
- Trial name
- ACTHAR (NCT01838174)
- Testing
- ACTHAR Gel (ACTH), IV methylprednisolone (steroids)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Colorado, Denver
Neuromyelitis Optica
Safety and Tolerability of Rituximab in Neuromyelitis Optica
The goal of this research study is to investigate whether Rituximab is safe to use in patients suffering from NMO, or who are at high risk for developing NMO.
- Trial name
- NCT00501748
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Optic Neuritis
OCS-05 in Patients With Optic Neuritis
To evaluate the safety and tolerability of OCS-05 compared to placebo in patients with optic neuritis receiving the standard of care
- Trial name
- ACUITY (NCT04762017)
- Testing
- OCS-05 +SoC (corticosteroid) IV administration
- Where
- 4 sites in France
- Volunteers
- 36 people
- Sponsor
- Oculis
Neuromyelitis Optica Spectrum Disorder Attack
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG).
- Trial name
- EASE-NMO (NCT07184840)
- Testing
- Intravenous Methylprednisolone (IVMP), Complement protein C5 inhibitor
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University General Hospital
Optic Neuritis
Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
The goal of the study is to determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.
- Trial name
- ACHTAR (NCT01987167)
- Testing
- ACTHAR
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Neuro-Ophthalmologic Associates, PC
Acute Demylelinating Optic Neuritis
Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)
To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment
- Trial name
- NCT01757691
- Testing
- Fingolimod 0.5mg/daily
- Where
- 2 sites in United States, Spain
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals